title: Disseminated intravascular coagulation in cats.
abstract: The purpose of this study was to describe the clinical characteristics of cats with disseminated intravascular coagulation (DIC), including associated diseases and hemostatic abnormalities, and to identify risk factors for death and treatments that potentially altered outcome. Medical records for cats with DIC from 1990-2004 were evaluated retrospectively. Inclusion criteria were the presence of an underlying disorder associated with DIC and either postmortem examination findings of intravascular fibrin deposition or thrombosis, or both of 2 or more organs or coagulation profiles that meet 3 of 5 criteria: prolonged prothrombin time (PT), activated partial thromboplastin time (aPTT), presence of fibrin degradation products (FDP), low plasma fibrinogen (FIB) concentration, and thrombocytopenia (<160,000 platelets/microL). Signalment, historical data, clinical findings, clinicopathologic data, underlying disorders, management, and outcome were recorded. Forty-six cats fulfilled the criteria for DIC. Cats ranged in age from 7 weeks to 17 years (median, 9 years). Hemorrhage was noted in 7 of 46 cats (15%). Three of 46 cats (7%) survived, whereas 43 of 46 (93%) died or were euthanized. The most common underlying disorders were lymphoma, other forms of neoplasia, pancreatitis, and sepsis. There was no association detected between outcome and signalment; underlying disease; hemorrhage; abnormalities in aPTT, FIB, FDPs, platelet count; transfusion of blood products; and heparin therapy. However, the median PT of nonsurvivors was more prolonged than in survivors (P < .005). DIC in cats can result from a variety of neoplastic, infectious, and inflammatory disorders, and is associated with a high case fatality rate.
authors.affiliation: Division of Internal Medicine, College of Veterinary Medicine, University of Minnesota, St. Paul, MN, USA. estri010@umn.edu
authors.forename: Michael A
authors.initials: MA
authors.lastname: Estrin
authors.forename: Conni E
authors.initials: CE
authors.lastname: Wehausen
authors.forename: Carl R
authors.initials: CR
authors.lastname: Jessen
authors.forename: Justine A
authors.initials: JA
authors.lastname: Lee
mesh_terms: D000818:Animals; D001803:Blood Transfusion / Q000662:veterinary; D002371:Cat Diseases / Q000097:blood* / Q000209:etiology / Q000401:mortality / Q000628:therapy; D002415:Cats; D004211:Disseminated Intravascular Coagulation / Q000097:blood / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D005260:Female; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D006493:Heparin / Q000627:therapeutic use; D008297:Male; D010314:Partial Thromboplastin Time / Q000662:veterinary*; D011517:Prothrombin Time / Q000662:veterinary; D012189:Retrospective Studies; D012307:Risk Factors; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; D005340:Fibrinogen; D006493:Heparin